Skip to main content
. Author manuscript; available in PMC: 2013 Sep 9.
Published in final edited form as: J Med Syst. 2009 Aug;33(4):287–297. doi: 10.1007/s10916-008-9190-4

Table 5.

Adjusted 3-year economic attractiveness by chronic kidney disease and coronary artery disease treatment group

CAD Group 1 VD 2 VD 3 VD LMD
Normal–mild CKD
 PCI vs. medical $149,457/YOLS $140,129/YOLS $38,582/YOLS
 CABG vs. medical $332,506/YOLS $20,299/YOLS $28,588/YOLS
 CABG vs. PCI Dominated Dominant
Moderate–severe CKD
 PCI vs. medical $112,472/YOLS Dominant $89,364/YOLS
 CABG vs. medical $15,661/YOLS $91,583/YOLS $3709/YOLS
 CABG vs. PCI $36,593/YOLS $54,902/YOLS

CAD Coronary artery disease, VD ventricular disease, LMD left main disease, CKD chronic kidney disease